Personalized transcranial alternating current stimulation improves sleep quality: Initial findings.
V Ayanampudi1, V Kumar1, A Krishnan1
1StimScience Inc., Berkeley, CA, United States.
Frontiers in Human Neuroscience
|January 27, 2023
Summary
Personalized transcranial alternating current stimulation (tACS) significantly improved sleep duration and reduced the time to fall asleep. This non-invasive brain stimulation offers a promising alternative for sleep optimization, especially for individuals with insomnia.
Area of Science:
- Neuroscience
- Sleep Medicine
- Neuromodulation
Background:
- Insufficient sleep is a significant public health concern linked to numerous chronic diseases and mental health issues.
- Existing pharmacological treatments for sleep difficulties carry risks, necessitating the exploration of alternative interventions.
- Transcranial alternating current stimulation (tACS) is an emerging non-invasive brain stimulation technique with potential for sleep optimization.
Purpose of the Study:
- To investigate the efficacy of tACS in improving sleep quality and quantity.
- To compare a personalized tACS approach with a fixed stimulation protocol and a sham control condition.
- To evaluate the potential of tACS as a therapeutic intervention for sleep difficulties, including insomnia.
Main Methods:
- A within-subjects, randomized crossover design involving 25 participants (mean age 46.3 years).
- Two active tACS conditions (fixed 5/10 Hz and personalized peak EEG frequencies) and a null-stimulation control condition were administered.
- tACS was applied for 15 minutes pre-sleep, targeting theta/alpha frequency bands to modulate neural activity.
Main Results:
- Personalized tACS significantly increased sleep duration by 22 minutes compared to the control condition (p=0.04) and 19 minutes compared to fixed tACS (p=0.03).
- Personalized tACS reduced sleep onset time by 28% (6 minutes faster) compared to fixed tACS (p=0.02).
- In a subgroup with insomnia, personalized tACS improved sleep duration by 33 minutes versus fixed tACS (p=0.02) and 30 minutes versus control (p<0.1).
Conclusions:
- Personalized tACS demonstrates a significant benefit in improving sleep quantity and reducing sleep onset latency.
- The findings support personalized tACS as a viable non-invasive therapeutic strategy for enhancing sleep.
- Further large-scale trials are warranted to establish personalized tACS for treating sleep disorders like insomnia.
